Mengjie Li
Zhejiang Chinese Medical University(CN)Tongji University(CN)University of Science and Technology of China(CN)Nanchang University(CN)Henan University(CN)Nantong University(CN)Tianjin Medical University Cancer Institute and Hospital(CN)Zhengzhou University(CN)Soochow University(CN)Affiliated Hospital of Nantong University(CN)First Affiliated Hospital of Jiangxi Medical College(CN)Zhejiang Cancer Hospital(CN)Guangdong Academy of Sciences(CN)Ministry of Education(IR)People's Hospital of Cangzhou(CN)Dongzhimen Hospital Affiliated to Beijing University of Chinese Medicine(CN)National Clinical Research(US)Shanghai Tenth People's Hospital(CN)Affiliated Zhongshan Hospital of Dalian University(CN)Shenzhen Institutes of Advanced Technology(CN)Ministry of Agriculture and Rural Affairs(CN)National Institute Of Blood Disease and Bone Marrow Transplantation(PK)First Affiliated Hospital of Zhengzhou University(CN)Henan Provincial Center for Disease Control and Prevention(CN)Union Hospital(CN)First Affiliated Hospital of Nanchang University(CN)Institute of Zoology(CN)Zhejiang University(CN)Southeast University(CN)Yangzhou University(CN)Xinxiang Medical University(CN)
Publications by Year
Research Areas
Metabolomics and Mass Spectrometry Studies, RNA modifications and cancer, Cancer-related molecular mechanisms research, MicroRNA in disease regulation, Nanoplatforms for cancer theranostics
Most-Cited Works
- → Long Noncoding RNA GMAN, Up-regulated in Gastric Cancer Tissues, Is Associated With Metastasis in Patients and Promotes Translation of Ephrin A1 by Competitively Binding GMAN-AS(2018)272 cited
- → Fusobacterium nucleatum reduces METTL3-mediated m6A modification and contributes to colorectal cancer metastasis(2022)233 cited
- → Exploring the molecular basis of heterosis for plant breeding(2019)180 cited
- → Anti-metastasis activity of curcumin against breast cancer via the inhibition of stem cell-like properties and EMT(2018)155 cited
- → Differences in metabolite profile between blood plasma and serum(2010)145 cited
- → Far-Red Light-Activatable Prodrug of Paclitaxel for the Combined Effects of Photodynamic Therapy and Site-Specific Paclitaxel Chemotherapy(2016)120 cited